Functioning Pituitary Adenoma

Categories: Cancer diseases, Endocrine diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Functioning Pituitary Adenoma

MalaCards integrated aliases for Functioning Pituitary Adenoma:

Name: Functioning Pituitary Adenoma 11 58 14
Secretory Adenoma of the Pituitary Gland 11
Endocrine Active Pituitary Adenoma 58
Pituitary Adenoma, Functioning 71
Secreting Pituitary Adenoma 58


Orphanet: 58  
Rare endocrine diseases

External Ids:

Disease Ontology 11 DOID:5395
NCIt 49 C8388
UMLS via Orphanet 72 C0854486
Orphanet 58 ORPHA314753
UMLS 71 C0854486

Summaries for Functioning Pituitary Adenoma

MalaCards based summary: Functioning Pituitary Adenoma, also known as secretory adenoma of the pituitary gland, is related to functionless pituitary adenoma and tsh producing pituitary tumor. An important gene associated with Functioning Pituitary Adenoma is PRL (Prolactin), and among its related pathways/superpathways are GPCR downstream signalling and Signal Transduction. The drugs Metformin and Liraglutide have been mentioned in the context of this disorder. Affiliated tissues include pituitary, thyroid and bone, and related phenotypes are homeostasis/metabolism and nervous system

Related Diseases for Functioning Pituitary Adenoma

Diseases related to Functioning Pituitary Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 343)
# Related Disease Score Top Affiliating Genes
1 functionless pituitary adenoma 32.8 SST POMC IGF1
2 tsh producing pituitary tumor 32.0 USP8 TBX19 SSTR5 SST PRL POMC
3 growth hormone secreting pituitary adenoma 31.9 USP8 TBX19 SSTR5 SSTR2 SSTR1 SST
4 goiter 31.1 TRH SST PRL IGF1
5 pituitary tumors 31.0 SSTR5 SST PRL MEN1 IGF1
6 insulin-like growth factor i 31.0 SST PRL IGF1 GHRH
7 diabetes insipidus 31.0 PRL POMC CRH
8 premature ovarian failure 7 31.0 POMC CRH
9 acth-secreting pituitary adenoma 30.9 USP8 TBX19 SSTR5 SSTR2 SSTR1 SST
10 hypopituitarism 30.9 TRH TBX19 PRL POMC IGF1 GHRH
11 central diabetes insipidus 30.9 TRH PRL POMC IGF1
12 intracranial hypertension, idiopathic 30.8 SSTR1 POMC IGF1
13 pituitary adenoma 1, multiple types 30.8 SST PRL MEN1 IGF1 AIP
14 pituitary-dependent cushing's disease 30.8 USP8 TRH SST PRL POMC GHRH
15 adenoma 30.8 USP8 TRH SSTR5 SSTR2 SST PRL
16 pituitary apoplexy 30.7 TRH SST PRL POMC IGF1 AIP
17 craniopharyngioma 30.7 TRH PRL IGF1
18 fibrous dysplasia 30.6 SST PRL IGF1 GHRH
19 neuroendocrine tumor 30.6 SSTR2 SST POMC MEN1 IGF1
20 chromophobe adenoma 30.5 TRH PRL POMC
21 hypothyroidism, congenital, nongoitrous, 4 30.5 PRL POMC IGF1
22 abducens palsy 30.5 PRL POMC
23 carcinoid tumors, intestinal 30.5 SSTR2 SST MEN1
24 galactorrhea 30.5 PRL IGF1 DRD2
25 inappropriate adh syndrome 30.5 PRL POMC CRH
26 thyroid hormone resistance, selective pituitary 30.5 TRH SST
27 carcinoid syndrome 30.5 SST IGF1 GHRH
28 hyperprolactinemia 30.5 TRH SST PRL POMC IGF1 GHRH
29 zollinger-ellison syndrome 30.5 SST MEN1 GHRH
30 multiple endocrine neoplasia 30.5 SST PRL PRKAR1A POMC MEN1 AIP
31 adult syndrome 30.4 POMC IGF1 CRH
32 glucose intolerance 30.4 SST PRL POMC IGF1
33 empty sella syndrome 30.4 TRH PRL POMC IGF1
34 hypothyroidism 30.4 TRH SST PRL POMC IGF1 GHRH
35 paraganglioma 30.4 SSTR2 SST POMC MEN1
36 nelson syndrome 30.3 USP8 TBX19 SSTR5 SST PRL POMC
37 conn's syndrome 30.3 USP8 TRH TBX19 SST PRL PRKAR1A
38 hyperthyroidism 30.3 TRH SST PRL POMC IGF1
39 pituitary adenoma 30.3 USP8 TRH SSTR5 SSTR2 SSTR1 SST
40 acth deficiency, isolated 30.3 TRH TBX19 PRL POMC CRH
41 amenorrhea 30.3 TRH PRL POMC IGF1 CRH
42 pituitary hormone deficiency, combined, 2 30.3 TRH PRL POMC IGF1 GHRH
43 prolactin producing pituitary tumor 30.2 SSTR5 PRL POMC MEN1 IGF1 DRD2
44 gangliocytoma 30.2 TBX19 SST PRL POMC GHRH CRH
45 multiple endocrine neoplasia, type i 30.2 SSTR2 SST PRL PRKAR1A POMC MEN1
46 mccune-albright syndrome 30.1 USP8 SST PRL PRKAR1A POMC MEN1
47 hypoglycemia 30.0 TRH SST PRL POMC IGF1 GHRH
48 acromegaly 30.0 TRH SSTR5 SSTR2 SSTR1 SST PRL
49 pheochromocytoma 29.9 SSTR1 SST PRL POMC MEN1 IGF1
50 meningioma, familial 29.7 SSTR5 SSTR2 SSTR1 SST PRL PRKAR1A

Graphical network of the top 20 diseases related to Functioning Pituitary Adenoma:

Diseases related to Functioning Pituitary Adenoma

Symptoms & Phenotypes for Functioning Pituitary Adenoma

MGI Mouse Phenotypes related to Functioning Pituitary Adenoma:

# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.22 AIP CRH DRD2 GHRH IGF1 MEN1
2 nervous system MP:0003631 10.21 CRH DRD2 GHRH IGF1 MEN1 POMC
3 growth/size/body region MP:0005378 10.1 AIP CRH DRD2 GHRH IGF1 MEN1
4 liver/biliary system MP:0005370 10.06 AIP CRH DRD2 GHRH MEN1 POMC
5 neoplasm MP:0002006 10 AIP DRD2 IGF1 MEN1 POMC PRKAR1A
6 endocrine/exocrine gland MP:0005379 9.93 AIP CRH DRD2 GHRH IGF1 MEN1
7 adipose tissue MP:0005375 9.91 CRH DRD2 GHRH IGF1 POMC PRKAR1A
8 behavior/neurological MP:0005386 9.73 CRH DRD2 GHRH MEN1 POMC PRKAR1A
9 integument MP:0010771 9.28 AIP CRH DRD2 IGF1 POMC PRKAR1A

Drugs & Therapeutics for Functioning Pituitary Adenoma

Drugs for Functioning Pituitary Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 87)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
Liraglutide Approved Phase 4 204656-20-2 44147092 16134956
Pasireotide Approved Phase 4 396091-73-9 56841596 9941444
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605 16129706
Cabergoline Approved Phase 4 81409-90-7 54746
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
Lactitol Approved, Investigational Phase 4 585-86-4 157355
8 HIV Protease Inhibitors Phase 4
protease inhibitors Phase 4
10 Insulin, Globin Zinc Phase 4
Insulin Phase 4
Sitagliptin Phosphate Phase 4 654671-77-9
13 Dipeptidyl-Peptidase IV Inhibitors Phase 4
14 Incretins Phase 4
15 Hormones Phase 4
16 Hormone Antagonists Phase 4
17 Neurotransmitter Agents Phase 4
18 Dopamine agonists Phase 4
19 Dopamine Agents Phase 4
20 Antiparkinson Agents Phase 4
Hydrocortisone succinate Approved Phase 3 2203-97-6 3643
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 3640 5754
Ketoconazole Approved, Investigational Phase 3 65277-42-1, 142128-57-2 47576 3823 638701
Lanreotide Approved Phase 3 108736-35-2 71349 6918011
26 Hypoglycemic Agents Phase 2, Phase 3
27 Hydrocortisone 17-butyrate 21-propionate Phase 3
28 Melanocyte-Stimulating Hormones Phase 3
29 Adrenocorticotropic Hormone Phase 3
beta-Endorphin Phase 3
31 glucocorticoids Phase 2, Phase 3
32 Pharmaceutical Solutions Phase 3
Bexarotene Approved, Investigational Phase 1, Phase 2 153559-49-0 82146
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
Tannic acid Approved Phase 2 1401-55-4 16129878 16129778
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
Prednisolone Approved, Vet_approved Phase 2 50-24-8 4894 5755
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5 1875
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 4159 6741
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
Dexmedetomidine Approved, Experimental, Vet_approved Phase 2 86347-14-0, 113775-47-6 68602 5311068
Rosiglitazone Approved, Investigational Phase 2 122320-73-4, 155141-29-0 77999
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7 4897
Maleic acid Experimental, Investigational Phase 2 110-16-7, 110-17-8 444266 444972
47 Neuroprotective Agents Phase 2
Methylprednisolone Acetate Phase 2 584547
49 Protective Agents Phase 2
50 Histone Deacetylase Inhibitors Phase 2

Interventional clinical trials:

(show top 50) (show all 56)
# Name Status NCT ID Phase Drugs
1 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment: Correlation With Disease Activity, Insulin Sensitivity and Secretion Parameters Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
2 A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
3 An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment Active, not recruiting NCT01794793 Phase 4 Pasireotide;Cabergoline
4 A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease Completed NCT02697734 Phase 3 osilodrostat;osilodrostat Placebo
5 A Randomized, Double-blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide (SOM230) Subcutaneous (sc) Over a 6 Month Treatment Period in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3 Pasireotide
6 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3 Cabergoline
7 Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease Completed NCT02180217 Phase 3 osilodrostat;LCI699 matching placebo
8 Compassionate Use Protocol for the Administration of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3 Mifepristone
9 Prevention of Metabolic Complications of Glucocorticoid Excess - a Randomised, Doubleblind,Placebo Controlled Study Completed NCT01319994 Phase 2, Phase 3 Metformin;Placebo
10 A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease Completed NCT01374906 Phase 3 pasireotide LAR;SOM230 LAR 30 mg;SOM230 LAR 10 mg
11 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease (Seascape). Completed NCT01582061 Phase 3 Pasireotide sub-cutaneous
12 An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome Active, not recruiting NCT03621280 Phase 3 Levoketoconazole
13 Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma From an Endocrinological Point of View (MERGE Study): a Randomized, Phase 3 Trial Not yet recruiting NCT03439709 Phase 3 Lanreotide 60Mg Solution for Injection
14 An Open-label Study of the Safety, Pharmacokinetics and Pharmacodynamics of Mifepristone in Children With Refractory Cushing's Disease Withdrawn NCT01925092 Phase 3 mifepristone
15 Preoperative Bexarotene Treatment for Cushing's Disease Unknown status NCT00845351 Phase 1, Phase 2 Bexarotene
16 Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease Unknown status NCT02484755 Phase 2 Gefitinib
17 An Open-Label, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma Completed NCT01283542 Phase 2 Pasireotide LAR
18 Extension to a Multicenter, Open-label Study to Assess the Safety and Efficacy of 600 μg SOM230, Administered Subcutaneously, Bid in Patients With Cushing's Disease Completed NCT00171951 Phase 2 Pasireotide
19 Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition (TICSI) Completed NCT03111810 Phase 2 AZD4017 and prednisolone;Placebo Oral Tablet and prednisolone
20 A Multicenter, Open Label Study to Assess the Safety and Efficacy of 600 µg SOM230, Administered Subcutaneously, b.i.d. in Patients With Cushing's Disease Completed NCT00088608 Phase 2 SOM230 s.c.
21 A Proof of Concept, Open-label, Forced Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of 10-weeks Treatment of LCI699 in Patients With Cushing's Disease Completed NCT01331239 Phase 2 LCI699
22 A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's Disease Recruiting NCT03708900 Phase 2 LCI699
23 The Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing's Disease Recruiting NCT04339751 Phase 2 Vorinostat
24 SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome Recruiting NCT05307328 Phase 2 SPI-62;Placebo
25 A Phase 2 Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease Active, not recruiting NCT03774446 Phase 2 Seliciclib
26 Effect of Dexmedetomidine on Intraoperative Neuroendocrine Stress Response and Early Postoperative Quality of Recovery in Non-functioning Pituitary Adenoma Patients Undergoing Endoscopic Transsphenoidal Tumor Surgery Not yet recruiting NCT05005715 Phase 2 Dexmedetomidine;normal saline
27 A Phase II Trial to Assess the Efficacy and Safety of Pasireotide s.c. Alone or in Combination With Cabergoline in Patients With Cushing's Disease Terminated NCT01915303 Phase 2 Pasireotide with or without cabergoline
28 An Open Label, Multicenter Study Evaluating the Safety and Efficacy of Short Term (6 Weeks) Rosiglitazone Treatment in Patient's With Cushing's Disease Terminated NCT00612066 Phase 2 rosiglitazone maleate
29 Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine Terminated NCT02160730 Phase 2 R-roscovitine
30 Exploratory Phase 2 Study of Farletuzumab in Resectable Non-functioning Pituitary Adenoma Withdrawn NCT01203618 Phase 2 Farletuzumab
31 Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools Unknown status NCT01775332
32 Prospective Observational Study of Diagnostic Yield in Cushing's Disease Using Deep Learning Based Denoising MRI Unknown status NCT04121988
33 A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas Unknown status NCT03309319 Rosiglitazone
34 Etat de santé Des Patients Suivis Pour Une Maladie de Cushing Dans la région Grand-Ouest de 1990 à 2015 Unknown status NCT03297892
35 Cognitive Sequels of Cushing Syndrome Unknown status NCT02603653
36 Characteristics of Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects Completed NCT02574793
37 Evolution of the Metabolic, Cardiovascular, Bone Complications and of the Quality of Life in Cushing's Disease Completed NCT02568982
38 Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease Completed NCT03817840
39 Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease Completed NCT03346954
40 National Swedish Study in Cushing´s Disease Incidence and Outcomes Completed NCT02350153
41 Cognition, Steroids, and Imaging in Cushings Disease Completed NCT00081341
42 Rhinological Outcomes in Endonasal Pituitary Surgery: A Multi-Center Observational Cohort Study Completed NCT01504399
43 The Factors Associated With the Recurrence in Patients With Cushing Disease Completed NCT02233335
44 A Prospective, Multicenter, Randomized Controlled Study of Postoperative Thrombosis Prevention in Patients With Cushing's Disease Recruiting NCT04486859 LMWH/Rivaroxaban
45 Modulating the Glucose-dependent Insulinotropic Polypeptide (GIP) System in Patients With Acromegaly Due to a Pituitary Tumor Recruiting NCT03807076
46 Long-Term Follow-UP of Survivors of Pediatric Cushing Disease Recruiting NCT03831958
47 Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid Disorders Recruiting NCT04374721
48 Usefulness of Hair Cortisol/Cortisone Concentrations for the Monitoring of Medical Treatment in Patients With Cushing's Disease Recruiting NCT04201444
49 Non-interventional Study for the Generation of Long Term Safety and Efficacy Data of Pasireotide s.c. in Patients With Cushing's Disease (Post-Authorization Safety Study) Recruiting NCT02310269 SOM230
50 A Clinical and Genetic Investigation of Pituitary and HYPOTHALAMIC Tumors and Related Disorders Recruiting NCT00001595

Search NIH Clinical Center for Functioning Pituitary Adenoma

Genetic Tests for Functioning Pituitary Adenoma

Anatomical Context for Functioning Pituitary Adenoma

Organs/tissues related to Functioning Pituitary Adenoma:

MalaCards : Pituitary, Thyroid, Bone, Hypothalamus, Prostate, Skeletal Muscle, Pons

Publications for Functioning Pituitary Adenoma

Articles related to Functioning Pituitary Adenoma:

(show top 50) (show all 1131)
# Title Authors PMID Year
Treatment of Cushing's syndrome with osilodrostat: practical applications of recent studies with case examples. 62
36002784 2022
Treatment of non-functioning pituitary adenoma with cabergoline: a systematic review and meta-analysis. 62
35902444 2022
Impact of histopathological classification of non-functioning adenomas on long term outcomes: comparison of the 2004 and 2017 WHO classifications. 62
36261697 2022
Global changes in chromatin accessibility and transcription in growth hormone-secreting pituitary adenoma. 62
35947334 2022
Clinical Characteristics and Associated Factors of Colonic Polyps in Acromegaly. 62
36075228 2022
Effect of cabergoline on tumor remnant after surgery in nonfunctioning pituitary adenoma. 62
36355257 2022
A Comprehensive Review of Four Clinical Practice Guidelines of Acromegaly. 62
36105896 2022
The Endoscopic Endonasal Transsphenoidal Approach for Thyrotropin-Secreting Pituitary Adenomas: Single-Center Experience and Clinical Outcomes of 49 Patients. 62
36096394 2022
Development and testing of diagnostic algorithms to identify patients with acromegaly in Southern Italian claims databases. 62
36151305 2022
Comment on "Persistent remission of acromegaly in a patient with GH-secreting pituitary adenoma: Effect of treatment with pasireotide long-acting release and consequence of treatment withdrawal". 62
35313386 2022
DNA Methylation Profiling in Rare Sellar Tumors. 62
36140326 2022
A systematic review of molecular alterations in invasive non-functioning pituitary adenoma. 62
35711030 2022
Sevoflurane anesthesia rather than propofol anesthesia is associated with 3-month postoperative hypocortisolism in patients undergoing endoscopic transsphenoidal surgery for non-functional pituitary adenoma with preoperative normal hypothalamic-pituitary-adrenal axis. 62
35641648 2022
MicroRNA in Acromegaly: Involvement in the Pathogenesis and in the Response to First-Generation Somatostatin Receptor Ligands. 62
35955787 2022
A Case Report of a Thyrotropin-Secreting Pituitary Macroadenoma. 62
36035030 2022
Acromegaly: an endocrine pathology with serious consequences 62
35796476 2022
Natural history of pituitary apoplexy: a long-term follow-up study. 62
35701171 2022
Persistent remission of acromegaly in a patient with GH-secreting pituitary adenoma: Effect of treatment with pasireotide long-acting release and consequence of treatment withdrawal. 62
35167717 2022
Oral Octreotide: A Review of Recent Clinical Trials and Practical Recommendations for Its Use in the Treatment of Patients With Acromegaly. 62
35452815 2022
Transcription factor GTF2B regulates AIP protein expression in growth hormone-secreting pituitary adenomas and influences tumor phenotypes. 62
34932801 2022
A Factorial Analysis on Visual Outcomes of Transsphenoidal Surgery for Pituitary Macroadenoma. 62
36120608 2022
The intestinal flora of patients with GHPA affects the growth and the expression of PD-L1 of tumor. 62
34647152 2022
Determinants of Short-Term Weight Gain Following Surgical Treatment for Craniopharyngioma in Adults. 62
35184516 2022
Localization of TSH-secreting pituitary adenoma using 11C-methionine image subtraction. 62
35524902 2022
Recurrent Metatarsal Fractures in a Patient With Cushing Disease: A Case Report. 62
35712341 2022
Cushing Disease: Medical and Surgical Considerations. 62
35256173 2022
Ectopic Cushing's syndrome from an ACTH-producing pheochromocytoma with a non-functioning pituitary adenoma. 62
35319487 2022
Multivariable Diagnostic Prediction Model to Detect Hormone Secretion Profile From T2W MRI Radiomics with Artificial Neural Networks in Pituitary Adenomas. 62
35306784 2022
Misleading FT4 and FT3 Due to Immunoassay Interference From Autoantibodies. 62
34848174 2022
Pediatric adrenocortical adenoma presenting with Cushing’s syndrome 62
35249005 2022
Treatment Dilemma of Latrogenic Pseudoaneurysm of the Intracavernous Internal Carotid Artery in Young Girl Following Transnasal Transsphenoidal Surgery: A Case Report. 62
35873853 2022
Late onset of pituitary apoplexy following gonadotropin-releasing hormone agonist for prostate cancer treatment. 62
35256375 2022
Predictive factors of postoperative diabetes insipidus in 333 patients undergoing transsphenoidal surgery for non-functioning pituitary adenoma. 62
34283369 2022
Diagnosis and Treatment of Acromegaly: An Update. 62
35120696 2022
Characteristics of Gut Microbiota in Patients with GH-Secreting Pituitary Adenoma. 62
35019688 2022
Pituitary hyperplasia mimicking thyrotropin-producing pituitary adenoma in the patient with resistance to thyroid hormone: a case report. 62
32727243 2022
Osilodrostat for Cushing disease and its role in pediatrics. 62
35045421 2022
Application of Contrast-Enhanced 3-Dimensional T2-Weighted Volume Isotropic Turbo Spin Echo Acquisition Sequence in the Diagnosis of Prolactin-Secreting Pituitary Microadenomas. 62
35099143 2022
Endoscopic transsphenoidal surgery for non-functioning pituitary adenoma: Learning curve and surgical results in a prospective series during initial experience. 62
35983556 2022
Expression pattern of non-coding RNAs in non-functioning pituitary adenoma. 62
36119500 2022
Role of microRNAs in non-functioning pituitary adenoma. 62
35099451 2022
Association between overweight and growth hormone secretion in patients with non-functioning pituitary tumors. 62
35452483 2022
Surgery for acromegaly: Indications and goals. 62
35992136 2022
Ectopic Adrenocorticotropic Hormone-Secreting Pituitary Adenoma in the Clivus Region: A Case Report. 62
36062163 2022
Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis. 62
35846311 2022
Therapeutic difficulties in an aggressive ACTH-secreting pituitary adenoma. 62
35381097 2022
Case Report: Cytologic Description of Somatotroph Pituitary Adenoma in a Cat. 62
35923821 2022
A rare case of macroprolactinoma in a patient with Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome. 62
34889204 2021
Syndrome of inappropriate secretion of thyroid-stimulating hormone in a subject with galactorrhea and menstrual disorder and undergoing infertility treatment: Case report. 62
34967378 2021
Pseudocapsular resection in elderly patients with non-functioning pituitary adenoma. 62
34741976 2021

Variations for Functioning Pituitary Adenoma

Expression for Functioning Pituitary Adenoma

Search GEO for disease gene expression data for Functioning Pituitary Adenoma.

Pathways for Functioning Pituitary Adenoma

GO Terms for Functioning Pituitary Adenoma

Biological processes related to Functioning Pituitary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.88 SSTR5 SSTR2 SSTR1
2 negative regulation of cell population proliferation GO:0008285 9.77 SSTR5 SSTR2 SSTR1 SST MIR93 MEN1
3 neuropeptide signaling pathway GO:0007218 9.76 POMC SSTR1 SSTR2 SSTR5
4 forebrain development GO:0030900 9.72 SSTR2 SSTR1 DRD2
5 positive regulation of growth hormone secretion GO:0060124 9.67 GHRH DRD2
6 adenohypophysis development GO:0021984 9.56 GHRH DRD2
7 somatostatin signaling pathway GO:0038170 9.1 SSTR5 SSTR2 SSTR1

Molecular functions related to Functioning Pituitary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide binding GO:0042277 9.73 SSTR5 SSTR2 SSTR1
2 neuropeptide binding GO:0042923 9.63 SSTR5 SSTR2 SSTR1
3 somatostatin receptor activity GO:0004994 9.43 SSTR5 SSTR2 SSTR1
4 hormone activity GO:0005179 9.4 TRH SST PRL POMC IGF1 GHRH

Sources for Functioning Pituitary Adenoma

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....